United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa 15 mg in 1.5 ml - thiotepa for injection, usp has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: - 1.adenocarcinoma of the breast. - 2.adenocarcinoma of the ovary. - 3.for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. - 4.for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.

European Union - English - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastic agents - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - thiotepa, quantity: 15 mg - injection, powder for - excipient ingredients: - thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumours: . adenocarcinoma of the breast or ovary; . for controlling intracavitary effusions secondary to diffuse or localised neoplastic diseases of various serosal cavities and . for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. complete response rates of 27% and 48% were obtained with a dose of30mg thiotepa in the treatment of bladder cancer.

Israel - English - Ministry of Health

a.l. medi-market ltd. - thiotepa - powder for concentrate for solution for infusion - thiotepa 100 mg/vial - thiotepa - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Israel - English - Ministry of Health

a.l. medi-market ltd. - thiotepa - powder for concentrate for solution for infusion - thiotepa 15 mg/vial - thiotepa - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:1. with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;2. when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - thiotepa - powder for concentrate for solution for infusion - thiotepa

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - thiotepa - powder for concentrate for solution for infusion - thiotepa

Australia - English - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - thiotepa, quantity: 100 mg - injection, powder for - excipient ingredients: - thiotepa-reach is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. (refer to section 5.2 clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - thiotepa, quantity: 15 mg - injection, powder for - excipient ingredients: - thiotepa-reach is indicated, in combination with other chemotherapy medicinal products: ? with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients; ? when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. (refer to section 5.2 clinical trials)

Canada - English - Health Canada

sterimax inc - thiotepa - powder for solution - 15mg - thiotepa 15mg